Fig. 7

Knockdown of TRIM45 can improve cognitive impairment and may be a target for treating patients with sepsis. a The levels of NLRP3, Gsdmd-N and TRIM45 in the mouse hippocampus were measured by western blotting; n ≥ 3 per group. b The numbers of Gsdmd⁺/DAPI and NLRP3⁺/DAPI positive cells in the hippocampus were measured by immunofluorescence staining. Scale bar, 10 µm; n = 3 per group. c The levels of secreted IL-6 and TNF-α were determined by flow cytometry; n ≥ 3 per group. d The levels of secreted IL-1β and IL-18 were determined by ELISA; n = 3 per group. e Flow cytometric analysis of M1 (CD86⁺) mononuclear macrophages in the serum of different groups of mice; n = 3 per group. f 7-day survival rates of mice induced by LPS. n = 12 per group. #P < 0.05 Sham vs. LPS, *P < 0.05 LPS vs. LPS + AAV-TRIM45. g Morris experiment and corresponding statistical analysis; n ≥ 8 per group. h The levels of TRIM45 in peripheral blood monocytes were measured by western blotting (c: control, s: sepsis); n = 5 per group. i Relation between TRIM45 and the GCS score; Group 1: GCS score of patients ≤ 8, n = 26; Group 2: GCS score of patients > 9, n = 6. J Correlation between TRIM45 expression and Acute Physiologic and Chronic Health Evaluation II scores in septic patients (R² = 0.9342, P < 0.0001); n = 44. k Correlation between TRIM45 expression and SOFA scores in septic patients (R² = 0.3365, P < 0.0001); n = 44. Data in f were assessed by the Kaplan–Meier log-rank test. Data in j, k were analysed by Spearman correlation test. Data in i were analysed by unpaired t test, and others were analysed by one-way ANOVA followed by Dunnett’s post hoc test. Data are presented as the mean ± S.E.M. from at least three independent experiments. n.s. for P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001